Chemotherapy-related skin toxicities
Acneiform eruptions, or folliculitis, often begin as facial erythema that progress to papules and pustules and spread to the upper trunk. Causes of folliculitis in cancer patients include actinomycin-D (Cosmegen)—the most common—as well as epidermal growth factor receptor-inhibiting agents, such as gefitinib (Iressa) and cetuximab (Erbitux). Although the pustules contain no bacteria, oral tetracycline antibiotics can be used to manage eruptions due to the drugs’ anti-inflammatory properties.
Paronychia is an infection of the soft tissue around a finger or toenail leading to inflammation and swelling. It is a known toxicity of anti-cancer therapy with epidermal growth factor receptor-inhibiting (EGFR) agents. These drugs may affect the skin’s epidermal receptors and cause paronychia. Onset is typically within 2 months of initiating an EGFR agent, with reported incidence rates ranging between 6% and 50%.
Trichomegaly, the spontaneous, excessive growth of eyelash with a specifically curly texture, is a toxicity associated with epidermal growth factor receptor-inhibiting (EGFR) use, particularly erlotinib (Tarceva, generic), gefitinib (Iressa), and cetuximab (Erbitux). Researchers hypothesize that trichomegaly may help predict tumor response during EGFR blockade treatment. The biologic significance of trichomegaly remains unknown.
Patients undergoing chemotherapy with taxanes (docetaxel [Docefrez, Taxotere, generics] and paclitaxel [Abraxane, generics]) and anthracyclines (doxorubicin [Doxil, generics], idarubicin [Idamycin PFS, generics], and epirubicin [Ellence, generics]) are prone to nail changes including Beau line or transverse grooves in the nail plate (pictured), onycholysis, onychomadesis, and thickening/thinning of the nail. Nail pain may require pain medication. New growth typically resolves these conditions.
The chemotherapy drugs fluorouracil (Carac, Effudex, Fluoroplex, generics), vinorelbine (Navelbine, generics), and daunorubicin (Cerubidine, Daunoxome) cause hyperpigmentation of the skin, nails, and oral mucosa. Hyperpigmentation can follow the distribution of veins, known as serpentine supravenous hyperpigmentation, or can be patchy and macular. Topical hydroquinone can decrease melanin production and help clear hyperpigmentation. The disorder typically resolves when chemotherapy is stopped.
The incidence of cancer diagnoses is increasing worldwide as the world’s population grows and people continue to live longer. As a result, chemotherapy-related skin toxicities are on the rise and clinicians and patients alike should be prepared to recognize these disorders.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|